Kura Oncology

US · KURA #3283 by market cap Listed 2015

10.67 +0.14 +1.33%

Live - 5344 symbols - heartbeat 290s ago · 2026-10-08 09:19

Pre-market 10.79 +1.12%

After-hours 10.67 0.00%

Market cap: 949.21M
P/E (TTM): -3.17
P/B: 19.61
EPS: -3.18
Div yield: 0.00%
52W pos: 51%

Reader sentiment Are you bullish or bearish on KURA?

Anonymous reader poll. Unscientific, not investment advice.

About Kura Oncology

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Founded: 2014
CEO: Dr. Troy E. Wilson, PhD, J.D.
Employees: 260
Headquarters: San Diego, California, United States of America
Fiscal year end: 12-31
Website: kuraoncology.com

Company profile

Exchange: US
Symbol: KURA
Market-cap rank: #3283
Listing date: 2015-11-05
Market cap: 949.21M
Float cap: 752.54M
Shares out: 88.96M
Float shares: 70.53M

Sectors & themes

Biotechnology Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 09:19:36 · For reference only, not investment advice and not tailored to your situation.